Erythropoetin Neuroprotection for Neonatal Cardiac Surgery

Baylor College of Medicine

Status and phase: Completed; Phase 2; Phase 1

Conditions: Transposition of the Great Arteries; Hypoplastic Left Heart Syndrome; Aortic Arch Hypoplasia or Interruption; Congenital Heart Disease

Treatments: Drug: Erythropoetin; Drug: Normal saline

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT00513240

IND #100011 (Other Identifier)

0942 (Other Grant/Funding Number)

Not Assigned (Other Grant/Funding Number)

1R21HD055501-01 (U.S. NIH Grant/Contract)

R21HD5550101

Details and patient eligibility

About

Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning disorders and hyperactivity syndromes. This study aims to determine if erythropoetin, a natural hormone made in the body, protects the brain from damage when given in high doses before and during neonatal open heart surgery. We will use brain MRI, brain wave tests (EEG), neurological examination, and long term developmental outcome testing to see if erythropoetin is better than salt water injection (placebo) in protecting the brain.

Full description

Hypothesis: Erythropoetin (EPO) will protect the neonatal brain in the perioperative period for congenital heart surgery.

Using a prospective, randomized, placebo-controlled, double-blinded design, the specific aims of this study are:

1. To determine the effect of perioperative EPO on short and long term neurological outcomes in neonates undergoing cardiac surgery with an optimized cardiopulmonary bypass strategy.
2. To determine EPO tolerability and safety with short term administration.
3. To determine EPO pharmacokinetics in this population.
4. To determine the relationship of neurological monitoring, specifically NIRS, to neurological outcomes with an optimized cardiopulmonary bypass technique in neonates that avoids deep hypothermic circulatory arrest, and to determine if EPO affects this relationship.

Protocol: Neonates undergoing arterial switch, Norwood, or aortic arch advancement/other complete 2 ventricle repair, >35 weeks gestation and ≥2.0 kg are eligible.

Preop day 1:NIRS for 12-24 hours, neuro exam, and Study drug dose #1: EPO 500 units/kg or saline placebo 12-72 hours before surgery. EPO Pharmacokinetic data for 25-50 consenting patients.

Day of surgery: Brain MRI immediately preop. Anesthesia/CPB per our standard practice (fentanyl 100-200 mcg/kg, midazolam, isoflurane, epsilon-aminocaproic acid, 75 mg/kg IV load to patient and CPB prime, and 75 mg/kg/hr infusion in OR) with ACP guided by TCD, pH stat, hct 30-35, avoid DHCA.

POD #1: Study drug dose #2: EPO 500 units/kg or saline placebo 24 hours after dose #2.

For 72 hours postop, NIRS monitoring. All monitor data collected electronically.

POD #3: Study drug dose #3: EPO 500 units/kg or saline placebo 48 hours after dose #3.

7 days postop: Brain MRI. (pentobarbital IV). Neuro exam before discharge. 3-6 months: Brain MRI immediately before or after 2nd surgery, or as outpatient (IV pentobarb or propofol/midazolam-may use N2O/sevo for induction, cannot intubate if outpatient; OR if cardiac MRI at same time, any indicated anesthetic technique). NIRS x 24h after 2nd surgery.

1,and 3 years: Bayley Scales of Infant Development III. 5 years: Battery of neurodevelopmental tests.

Early primary outcome variable: MRI severity of injury score (decrease by 25%). Late outcome variable Bayley Scales of Infant Development score: improvement by 18% at age 1 years.

Sample size: 60 patients: stratified into 3 groups to give power 0.85, alpha 0.05. Expect to accrue 2-4 patients per month.

Enrollment: 62 patients

Sex: All

Ages: 1 to 30 days old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Neonates (<30 days) undergoing cardiac surgery with cardiopulmonary bypass will be enrolled.

• Inclusion criteria include patients with:

  • single ventricle: hypoplastic left heart syndrome or variant undergoing Norwood Stage I or Sano palliation (SV group);
  • patients with D-transposition of the great vessels with or without ventricular septal defect (VSD) undergoing arterial switch operation with VSD closure if needed (ASO group); and
  • patients with interrupted or hypoplastic aortic arch with intracardiac defects (VSD, ASD, or subaortic stenosis) who are undergoing complete 2- ventricle repair including aortic arch advancement(AAA group), any other 2 ventricle lesion scheduled for complex anatomic repair.

Exclusion criteria

• Gestational age less than 35 weeks at birth
• Weight less than 2 kg
• Known recognizable dysmorphic syndrome
• Surgery not requiring cardiopulmonary bypass
• Preoperative cardiac arrest requiring chest compressions for greater than 3 minutes
• Inability to enroll the patient greater than 12 hours preoperatively
• Aortic crossclamping is not used
• CPB times are anticipated to be less than 60 minutes
• A nadir temperature on bypass greater than 25° C is planned.
• Presence of known contraindications to EPO administration-sustained systolic blood pressure >100, hemoglobin .18 g/dL, known allergy to EPO or one of its components
• Platelet count >600,000 per dL, INR <0.8.
• Maternal history of major vascular thrombosis, or multiple fetal loss (3 or more spontaneous abortions).

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

62 participants in 2 patient groups, including a placebo group

EPO group

Experimental group

Description:

Patients randomized to receive the 3 doses of erythropoetin.

Treatment:

Drug: Erythropoetin

Control group.

Placebo Comparator group

Description:

Patients randomized to receive 3 doses of normal saline control.

Treatment:

Drug: Normal saline